<DOC>
	<DOC>NCT01238497</DOC>
	<brief_summary>This registry is to expand upon existing data sets, to identify patient characteristics and indicators related to complications and clinical benefits for patients with symptomatic severe calcific degenerative aortic stenosis that are undergoing treatment with the commercially available Edwards SAPIEN XT™ Valve, and delivery devices.</brief_summary>
	<brief_title>SOURCE XT REGISTRY</brief_title>
	<detailed_description>Consecutive patient data should be collected at discharge, 30 days and 12 months post-implant. Subsets of patients may undergo additional follow-up.</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>The SAPIEN XT™ THV is indicated for use in patients with symptomatic aortic stenosis requiring TAVI who have a high risk for operative mortality, or are "nonoperable" Nonvalvular or congenital aortic stenosis Preexisting prosthetic heart valve in the Aortic position or a noncalcified aortic valve Severe (&gt;3+) mitral insufficiency or aortic regurgitation &gt; 3+ Active bacterial endocarditis or other active infections Severe ventricular dysfunction with ejection fraction &lt; 20% Coronary artery diseaserelated unstable angina Inability to tolerate anticoagulation / antiplatelet therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>SAPIEN XT™</keyword>
	<keyword>Transfemoral</keyword>
	<keyword>NovaFlex</keyword>
	<keyword>NovaFlex+</keyword>
	<keyword>NF</keyword>
	<keyword>NF+</keyword>
	<keyword>Transapical</keyword>
	<keyword>Transaortic</keyword>
	<keyword>Ascendra2</keyword>
	<keyword>Ascendra+</keyword>
	<keyword>Asc+</keyword>
	<keyword>aortic stenosis</keyword>
	<keyword>aortic valve</keyword>
	<keyword>Transcatheter Heart Valve</keyword>
	<keyword>THV</keyword>
</DOC>